

BioGaia appoints new Managing Director

BioGaia's Board of Directors has decided to appoint Axel Sjöblad as the new Managing Director of BioGaia AB. Peter Rothschild has been appointed as Group President.

It is with satisfaction that BioGaia announces this change, which will enable the company to increase its focus on sales and marketing while at the same time realising the major development potential that the Board sees for the Group.

Axel Sjöblad, who is currently Managing Director of Getinge Sverige AB and VP North and Central Europe and was previously Regional VP Northern European Markets at Gambro Lundia AB, will assume duties as Managing Director of BioGaia AB by 1 March 2016 at the latest. His extensive experience in marketing and sales makes him ideally suited to take over management of the company's operations, initially with a special focus on marketing and sales.

In the capacity of Group President, Peter Rothschild will retain overall responsibility for the BioGaia Group's research and development activities and will serve as working Chairman of the group companies **TwoPac** (BioGaia's production company), **IBT** (BioGaia's venture to develop a drug for premature newborns), and **CapAble** (BioGaia's venture in innovative delivery systems). He will also support the development of **BioGaia Japan**. Furthermore, Peter Rothschild will continue as Chairman of **Metabogen** (BioGaia's investment in development of microbiome-based products and concepts).

Through this organisational change, BioGaia will be able to reinforce its sales capabilities and the geographic expansion of its business. At the same time, it will enable the company to increase the focus on its subsidiaries and associated companies, as well as the major development potential that the Board sees for the Group.

"Axel Sjöblad has extensive experience of and an impressive track record in the healthcare and life sciences area through his earlier positions in the Gambro and Getinge groups. The Board is confident that Axel Sjöblad is well suited to take over as Managing Director of BioGaia's business, which Peter Rothschild has so brilliantly built up during his time at the helm. We are delighted that Peter Rothschild will continue in a key position for the company's development," says David Dangoor, Board Chairman.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm. www.biogaia.com

Press Release, 20 October 2015

Peter Rothschild, who founded the company in 1990 together with Jan Annwall, has guided BioGaia's establishment and successful development as Managing Director of BioGaia for 19 years, of which 17 years on the stock exchange. In his active role as Group President, Peter Rothschild will continue to lead the Group's promising strategic development.

For more information

David Dangoor, Chairman: +1 (212) 888 3300
Peter Rothschild, President: +46 8 555 293 00

Latest press releases from BioGaia

2015-10-12 BioGaia's probiotic shown to promote growth and prevent recurrent diarrhoea
2015-09-07 BioGaia to invest further in Infant Bacterial Therapeutics AB
2015-08-18 BioGaia AB – Interim report 1 January – 30 June 2015

BioGaia has published this information in accordance with the Swedish Securities Act. The information was issued for publication on 20 October 2015, 8:45 a.m.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm. www.biogaia.com